IRulya Therapeutics Inc. (IRLA) stock
IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$39.80+0.02 (+0.05%)
Close on Nov 13, 2026Market cap $40.48MP/E –Yield –
IRulya Therapeutics total assets
Total assets on the balance sheet at the end of each period.
IRulya Therapeutics's total assets was $106.47M at Sep 30, 2026. For fiscal 2025 it was $93.52M, down 18.3% from the year before. The highest annual figure on record is $189.47M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.52M | -18.3% |
| FY2024 | Dec 31, 2024 | $114.48M | -31.8% |
| FY2023 | Dec 31, 2023 | $167.90M | +61.6% |
| FY2022 | Dec 31, 2022 | $103.91M | -22.0% |
| FY2021 | Dec 31, 2021 | $133.23M | -29.7% |
| FY2020 | Dec 31, 2020 | $189.47M | +52.3% |
| FY2019 | Dec 31, 2019 | $124.37M | +70.7% |
| FY2018 | Dec 31, 2018 | $72.88M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $106.47M | -3.1% |
| Q2 FY2026 | Jun 30, 2026 | $124.00M | +5.8% |
| Q1 FY2026 | Mar 31, 2026 | $26.62M | -75.1% |
| Q4 FY2025 | Dec 31, 2025 | $93.52M | -18.3% |
| Q3 FY2025 | Sep 30, 2025 | $109.90M | -13.1% |
| Q2 FY2025 | Jun 30, 2025 | $117.21M | -13.1% |
| Q1 FY2025 | Mar 31, 2025 | $107.09M | -32.8% |
| Q4 FY2024 | Dec 31, 2024 | $114.48M | -31.8% |
| Q3 FY2024 | Sep 30, 2024 | $126.52M | +48.2% |
| Q2 FY2024 | Jun 30, 2024 | $134.83M | +51.8% |
| Q1 FY2024 | Mar 31, 2024 | $159.29M | +70.7% |
| Q4 FY2023 | Dec 31, 2023 | $167.90M | +61.6% |
| Q3 FY2023 | Sep 30, 2023 | $85.39M | -22.2% |
| Q2 FY2023 | Jun 30, 2023 | $88.84M | -24.6% |
| Q1 FY2023 | Mar 31, 2023 | $93.32M | -19.6% |
| Q4 FY2022 | Dec 31, 2022 | $103.91M | -22.0% |
| Q3 FY2022 | Sep 30, 2022 | $109.78M | -25.5% |
| Q2 FY2022 | Jun 30, 2022 | $117.86M | -27.0% |
| Q1 FY2022 | Mar 31, 2022 | $116.13M | -33.5% |
| Q4 FY2021 | Dec 31, 2021 | $133.23M | -29.7% |
| Q3 FY2021 | Sep 30, 2021 | $147.42M | -28.0% |
| Q2 FY2021 | Jun 30, 2021 | $161.39M | -26.4% |
| Q1 FY2021 | Mar 31, 2021 | $174.52M | -24.5% |
| Q4 FY2020 | Dec 31, 2020 | $189.47M | +52.3% |
| Q3 FY2020 | Sep 30, 2020 | $204.66M | +53.4% |
| Q2 FY2020 | Jun 30, 2020 | $219.21M | +53.0% |
| Q1 FY2020 | Mar 31, 2020 | $231.21M | +227.5% |
| Q4 FY2019 | Dec 31, 2019 | $124.37M | +70.7% |
| Q3 FY2019 | Sep 30, 2019 | $133.41M | – |
| Q2 FY2019 | Jun 30, 2019 | $143.24M | – |
| Q1 FY2019 | Mar 31, 2019 | $70.60M | – |
| Q4 FY2018 | Dec 31, 2018 | $72.88M | – |
See a number that looks wrong?